GRFS - Grifols, S.A.
| Previous Close | 18.96 |
| Open | 19.10 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1400 |
| Day's Range | 19.07 - 19.48 |
| 52 Week Range | 17.42 - 25.18 |
| Volume | 1,164,179 |
| Avg. Volume | 1,055,830 |
| Market Cap | 16.693B |
| Beta (3Y Monthly) | 1.04 |
| PE Ratio (TTM) | 31.83 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.46 (2.37%) |
| Ex-Dividend Date | 2018-11-30 |
| 1y Target Est | N/A |
- PR Newswire•9 days ago
Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions
- Erytra Eflexis is a fully automated, benchtop analyzer that performs pretransfusion compatibility testing - This system incorporates two laboratory configurations in a single instrument, providing laboratory ...
- PR Newswire•3 months ago
Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol
- AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients. BARCELONA, Spain, Oct. 27, 2018 /PRNewswire/ -- Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer's disease.
- PR Newswire•3 months ago
FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing
Test Offers Shortest Time to Reportable Results For US Hospitals, Reference Labs and Blood Centers - Efficient system analyzes 37 antigens of 10 blood group systems - Helps minimize allo-immunization risk ...
- PR Newswire•3 months ago
Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support
- Plasma-derived medicines replace missing or deficient proteins with healthy proteins that are obtained through human plasma donations. - Grifols' continued commitment to patients is evidenced by the expansion of its plasma donor center network and innovations for treatments of serious, rare and life-threatening illnesses. - Grifols is conducting clinical research on Alzheimer's disease.
- PR Newswire•4 months ago
Grifols Announces the Opening of Biotest Pharmaceuticals Corporation's Newest Plasma Donor Center in Bowling Green, Ohio
BOWLING GREEN, Ohio, Sept. 24, 2018 /PRNewswire/ -- Grifols is pleased to announce the opening of its newest Biotest Pharmaceuticals Corporation (BPC) plasma donor center located at 1616 East Wooster Street, Bowling Green, Ohio.
- PR Newswire•5 months ago
Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
Additional submissions to the FDA are planned to relocate the production of other licensed recombinant protein products. The transition is targeted for completion in mid-2019, pending the FDA approvals for the licensed antigens. Once the transition is complete, Grifols will have transferred 21 products to CMF.
- PR Newswire•5 months ago
Procleix® Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix® Panther® System
- Procleix Zika Virus assay approved for the detection of viral RNA in plasma and serum specimens, previously used since June 2016 under IND protocol - Procleix Zika Virus assay provides U.S. blood banks ...
- ACCESSWIRE•7 months ago
Free Technical Research on ImmunoGen and Three More Biotech Equities
On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN).
- PR Newswire•7 months ago
Grifols Expands its NAT Solutions Portfolio with New FDA Approvals for Two Assays
- Grifols Procleix Ultrio Elite assay screens for HIV-1, HCV, and HBV and detects HIV-2; the Procleix WNV assay screens for West Nile virus - Both assays are approved to run on the fully automated NAT ...
- PR Newswire•8 months ago
Grifols Launches a New Testing Service for Patients Treated with Daratumumab
BARCELONA, Spain, May 31, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the leading companies in the world in plasma-derived biological medicines and transfusion medicine, today announced it is adding a Daratumumab neutralization testing service to its extensive menu of services offered at Grifols Immunohematology Center laboratory (San Marcos, Texas). This new test facilitates complete antibody screening and identification in pretransfusion testing of patients under this therapy.
- PR Newswire•8 months ago
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents
- Grifols conventional antisera reagents recently received licensing approval by the U.S. Food & Drug Administration for manual testing in immunohematology laboratories - The addition of antisera reagents ...
- PR Newswire•9 months ago
Grifols donates over 25 million international units of blood clotting factor in 2017
BARCELONA, Spain, April 16, 2018 /PRNewswire/ -- Today, Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced it has donated over 25 million international units (IU) of blood clotting factor medicines over the last year. This donation is part of Grifols' commitment to provide a minimum of 200M IU to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over eight years starting in 2014. An estimated 400,000 people around the world have hemophilia, yet only 25% receive adequate treatment.
- PR Newswire•9 months ago
Grifols 2017 Annual Report on Form 20-F filed with the SEC on April 6, 2018
BARCELONA, Spain , April 6, 2018 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2017 Annual Report on Form 20-F with the United ...
- PR Newswire•10 months ago
Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S.
- The FDA approval received in 2017 allows Grifols to market its Normal Saline solution in 500mL polypropylene bags in the U.S. to mitigate the current shortage of Normal Saline in this market - This agreement ...
- PR Newswire•11 months ago
Grifols Shines Light on Rare Disease with Launch of Educational Campaign "Look Into Genetic COPD"
Alpha-1 is often overshadowed by patients' smoking history, even though guidelines from the World Health Organization, the American Thoracic Society, and the COPD Foundation recommend testing all people with COPD for alpha-1, regardless of their age or smoking history. "Alpha-1 is a debilitating rare disease that is often overlooked," said Bill Zabel, President, Grifols North America Sales and Commercial Operations.
- PR Newswire•11 months ago
Grifols HyperRAB® (rabies immune globulin ) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
BARCELONA, Spain, Feb. 6, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and immune globulin products for patients, has received approval from the U.S. Food & Drug Administration (FDA) for a new higher potency formulation of its HyperRAB® rabies immune globulin [human] for rabies postexposure prophylaxis (treatment of a person immediately after exposure to the rabies virus). The new formulation is twice the potency (300 IU/mL) of currently available rabies immune globulin options, offering a greater concentration of anti-rabies virus antibodies within each mL of volume, and for patients, the potential for fewer injections by significantly reducing the volume of medication administered in each dose.